All In Biotech

Drug Trial Radar · NCT07221162

A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes

A Phase 1, Open-Label, Safety and Immunogenicity Trial of Boost-2867, an IgG-Fc-RBD Fusion Protein Next Generation SARS-CoV-2 Booster Vaccine, Via Intranasal and Intramuscular Routes in Previously Vaccinated Adults

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

140

Actual

Start

Dec 5, 2025

Primary completion

Nov 24, 2026

Study completion Nov 24, 2026

Sponsor

Sponsor type
NIH
First posted
Oct 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of Boost-2867, given intramuscular (IM) with or without adjuvant or intranasal (IN) without adjuvant, as a booster dose to previously vaccinated healthy adults. Each of the study sites will be assigned to enroll either only participants who will receive IM administration (up to 5 sites) or only participants who will receive IN administration (up to 5 sites); no site will administer both IM and IN study product administrations. Within the IM and IN Arms the cohorts will be sequentially enrolled. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating one dose level of Boost-2867 without adjuvant administered IM, three dose levels of Boost-2867 with adjuvant administered IM, and three dose levels of Boost-2867 without adjuvant administered IN. A sample size of 140 participants (20 participants per dose cohort) is anticipated. To evaluate for early safety signals for this first-in-human trial, study product administration of participants enrolled for IM administration and those enrolled for IN administration will proceed in a staged fashion. For Cohorts 1 (IM administration without adjuvant) and 5 (IN administration), which may be enrolled and dosed concurrently, 3 sentinel participants under 50 years of age will be enrolled in each Cohort over at least 2 days. For each of those Cohorts independently, a safety review of halting rules and clinical safety data through at least Day 8 will be conducted by the Protocol Safety Review Team (PSRT) prior to enrollment of the remainder of the cohort. Enrollment, dosing, and safety oversight for IM Cohorts 2, 3, and 4 will proceed in the same fashion as Cohort 1, except that sentinel enrollment need not be spaced over at least 2 days. Similarly, for IN Cohorts 6 and 7, enrollment and safety oversight will proceed in the same fashion as Cohort 5, except that sentinel enrollment need not be spaced over at least 2 days. The primary objectives are: 1) To evaluate the safety and reactogenicity of a single IM injection of three different antigen dose levels (5, 15, and 50 microgram) of Boost-2867 with Alhydrogel (R) (alum) and CpG 7909 adjuvants, and a single injection of 50 microgram Boost-2867 without adjuvant, in previously vaccinated healthy adults. 2) To evaluate the safety and reactogenicity of a single IN administration of three different antigen dose levels (20, 50, and 125 microgram) of Boost-2867 without adjuvant in previously vaccinated healthy adults.

Conditions

  • COVID-19

Interventions

  • Aluminum Hydroxide SuspensionDrug

    Aluminum hydroxide adjuvant.

  • Boost-2867Biological

    Boost-2867 is a recombinant \~50 kDa SARS-CoV-2 RBD (KP.2 variant) S1 subunit joined to a human IgG1 Fc, forming a \~100 kDa homodimer.

  • CpG 7909Biological

    CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant.

  • Sodium Chloride, 0.9%Other

    0.9% Sodium Chloride Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of abnormal clinical safety laboratory adverse events.Time frame: Through day 8
  2. Occurrence of adverse events of special interest (AESIs).Time frame: Through 6 months
  3. Occurrence of medically attended adverse events (MAAEs).Time frame: Through 6 months
  4. Occurrence of new onset chronic medical conditions (NOCMCs).Time frame: Through 6 months
  5. Occurrence of potentially immune-mediated diseases (pIMDs)Time frame: Through 6 months
  6. Occurrence of Serious adverse events (SAEs).Time frame: Through 6 months
  7. Occurrence of solicited local adverse events (AEs).Time frame: Through 7 days
  8. Occurrence of solicited systemic adverse events (AEs).Time frame: Through 7 days
  9. Occurrence of unsolicited adverse events (AEs).Time frame: Through 28 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine

    San Francisco, California

  • Center for Immunization Research, Johns Hopkins Bloomberg School Public Health

    Baltimore, Maryland

  • Saint Louis University Center for Vaccine Development

    St Louis, Missouri

  • University of Rochester Medical Center - Vaccine Research Unit

    Rochester, New York

  • Duke Vaccine and Trials Unit

    Durham, North Carolina

  • University of Pittsburgh - Medicine - Infectious Diseases

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Kaiser Permanente Washington Health Research Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.